Adeno-associated viral vectors and the retina.
Recombinant adeno-associated viral vectors have slowly been moving to the forefront of gene therapy experiments. Given the non-pathogenic nature, low immunogenicity, ease of delivery, persistence, and targeting possibilities of rAAV, it is poised to become a major player in retinal gene therapy.